Serum testosterone level, testosterone replacement treatment, and prostate cancer

Area of Science:

• Urology
• Endocrinology
• Oncology

Background:

• Rising interest in testosterone replacement therapy (TRT) for hypogonadism.
• Prostate cancer (PCa) is a significant concern in aging men.
• Urologists express concern regarding potential PCa risks associated with TRT.

Purpose of the Study:

• To review the relationship between sex hormones and prostate tissue.
• To analyze the causal link between testosterone and PCa development.
• To evaluate TRT's effects on high-risk PCa patients and those with existing PCa.
• To assess TRT's impact on serum prostate-specific antigen (PSA) levels.

Main Methods:

• Literature review of recent developments.
• Analysis of studies on sex hormone levels and prostate tissue.
• Examination of research on TRT in various patient groups.

Main Results:

• The review synthesizes current understanding of testosterone's role in prostate health.
• Evidence regarding testosterone's direct causal link to PCa development is analyzed.
• Data on TRT's safety and efficacy in patients with or at risk for PCa is discussed.
• Impact of TRT on PSA levels is examined.

Conclusions:

• Current evidence on TRT and prostate cancer risk is complex and evolving.
• TRT's suitability for patients with or at risk for PCa requires careful consideration.
• Further research is needed to clarify the long-term effects of TRT on prostate health.